Your Health, We Care
Release date: 2026-01-28 17:54:51 Recommended: 8
Rivimeinib is available in three tablet strengths: 25 mg, 110 mg, and 160 mg.
The most common side effects of Revuforj include bleeding, nausea and vomiting, muscle or joint pain, infections, abnormal liver function test results, febrile neutropenia, diarrhea or constipation, differentiation syndrome, cardiac rhythm changes, loss of appetite, fluid retention, and fatigue. If you experience any of these side effects that bother you, inform your healthcare provider. In addition, Revuforj may cause other unlisted side effects; if you suspect you have developed any drug-related side effects, contact your healthcare provider promptly.
Recommended Dosage of Rivimeinib (Revuforj) for Acute Leukemia or Acute Myeloid Leukemia (AML)
Without concomitant strong CYP3A4 inhibitors: 270 mg orally, twice daily
With concomitant strong CYP3A4 inhibitors: 160 mg orally, twice daily
Dosage is calculated based on body surface area (BSA), and the administered dose can be determined with reference to the table below:
Without concomitant strong CYP3A4 inhibitors: 160 mg/m² orally, twice daily
With concomitant strong CYP3A4 inhibitors: 95 mg/m² orally, twice daily
For the specific administered dose corresponding to the body surface area, please refer to the official prescribing information for Rivimeinib (Revuforj).
Active ingredient: Rivimeinib
Inactive ingredients: Microcrystalline cellulose, calcium hydrogen phosphate, crospovidone, hypromellose, sodium bicarbonate, colloidal silicon dioxide (hydrophobic), magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and red iron oxide.
The 110 mg strength tablets additionally contain yellow iron oxide.
The 160 mg strength tablets additionally contain FD&C Blue No.2/Indigo Carmine Aluminum Lake (approved by the drug regulatory authority).
